File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: Switching to lamivudine in entecavir-treated patients with undetectable HBV DNA - final results at 96 weeks
  • Basic View
  • Metadata View
  • XML View
TitleSwitching to lamivudine in entecavir-treated patients with undetectable HBV DNA - final results at 96 weeks
 
AuthorsFung, J
Lai, CL
Wong, D
Seto, WK
Yuen, MF
 
KeywordsMedical sciences
Gastroenterology
 
Issue Date2010
 
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
 
CitationThe 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 462 [How to Cite?]
DOI: http://dx.doi.org/10.1002/hep.23990
 
AbstractBACKGROUND: The aim of this study was to determine the efficacy of entecavir followed by lamivudine in patients with undetectable viral load and normal ALT after initial entecavir treatment. METHODS: This is a 2-year prospective trial of 50 patients treated on entecavir 0.5 mg daily for over 6 months, and had …
 
ISSN0270-9139
2013 Impact Factor: 11.190
 
DOIhttp://dx.doi.org/10.1002/hep.23990
 
DC FieldValue
dc.contributor.authorFung, J
 
dc.contributor.authorLai, CL
 
dc.contributor.authorWong, D
 
dc.contributor.authorSeto, WK
 
dc.contributor.authorYuen, MF
 
dc.date.accessioned2011-08-26T14:33:10Z
 
dc.date.available2011-08-26T14:33:10Z
 
dc.date.issued2010
 
dc.description.abstractBACKGROUND: The aim of this study was to determine the efficacy of entecavir followed by lamivudine in patients with undetectable viral load and normal ALT after initial entecavir treatment. METHODS: This is a 2-year prospective trial of 50 patients treated on entecavir 0.5 mg daily for over 6 months, and had …
 
dc.description.naturelink_to_OA_fulltext
 
dc.description.otherThe 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 462
 
dc.identifier.citationThe 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 462 [How to Cite?]
DOI: http://dx.doi.org/10.1002/hep.23990
 
dc.identifier.doihttp://dx.doi.org/10.1002/hep.23990
 
dc.identifier.epage549A
 
dc.identifier.hkuros190375
 
dc.identifier.issn0270-9139
2013 Impact Factor: 11.190
 
dc.identifier.issuesuppl. S1
 
dc.identifier.openurl
 
dc.identifier.spage549A
 
dc.identifier.urihttp://hdl.handle.net/10722/137775
 
dc.identifier.volume52
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
 
dc.relation.ispartofHepatology
 
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.
 
dc.subjectMedical sciences
 
dc.subjectGastroenterology
 
dc.titleSwitching to lamivudine in entecavir-treated patients with undetectable HBV DNA - final results at 96 weeks
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Fung, J</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<contributor.author>Wong, D</contributor.author>
<contributor.author>Seto, WK</contributor.author>
<contributor.author>Yuen, MF</contributor.author>
<date.accessioned>2011-08-26T14:33:10Z</date.accessioned>
<date.available>2011-08-26T14:33:10Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>The 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 462</identifier.citation>
<identifier.issn>0270-9139</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/137775</identifier.uri>
<description.abstract>BACKGROUND: The aim of this study was to determine the efficacy of entecavir followed by lamivudine in patients with undetectable viral load and normal ALT after initial entecavir treatment. METHODS: This is a 2-year prospective trial of 50 patients treated on entecavir 0.5 mg daily for over 6 months, and had &#8230;</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc. The Journal&apos;s web site is located at http://www.hepatology.org/</publisher>
<relation.ispartof>Hepatology</relation.ispartof>
<rights>Hepatology. Copyright &#169; John Wiley &amp; Sons, Inc.</rights>
<subject>Medical sciences</subject>
<subject>Gastroenterology</subject>
<title>Switching to lamivudine in entecavir-treated patients with undetectable HBV DNA -  final results at 96 weeks</title>
<type>Conference_Paper</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0270-9139&amp;volume=52&amp;issue=Suppl. S1&amp;spage=549A, abstract no. 462&amp;epage=&amp;date=2010&amp;atitle=Switching+to+lamivudine+in+entecavir-treated+patients+with+undetectable+HBV+DNA+-++final+results+at+96+weeks</identifier.openurl>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.doi>10.1002/hep.23990</identifier.doi>
<identifier.hkuros>190375</identifier.hkuros>
<identifier.volume>52</identifier.volume>
<identifier.issue>suppl. S1</identifier.issue>
<identifier.spage>549A</identifier.spage>
<identifier.epage>549A</identifier.epage>
<description.other>The 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 462</description.other>
<bitstream.url>http://hub.hku.hk/bitstream/10722/137775/1/re01.htm</bitstream.url>
</item>